GlassScriptPhysician profile
Jennifer Laporte
NPI 1568012797
$3,566.06
in general payments reported to CMS, 2019-2025
20 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $576 · 2022: $831 · 2023: $978 · 2024: $730 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,158.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $896.69 | 2021-2025 | Breztri, Farxiga, Tezspire |
| Glaxosmithkline, LLC. | $623.87 | 2022-2025 | Nucala, Arexvy |
| Novartis Pharmaceuticals Corporation | $369.26 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.91 | 2021-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $297.19 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $226.87 | 2023-2024 | Dupixent |
| United Therapeutics Corporation | $170.95 | 2023-2025 | |
| Novo Nordisk INC | $119.54 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $103.05 | 2022 | |
| Verona Pharma, INC. | $86.94 | 2025 | Ohtuvayre |
| Medtronic, INC. | $80.39 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.98 | 2023-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.92 | 2022-2023 | Xifaxan |
| Kestra Medical Technology Services, INC. | $38.73 | 2023 | Assure Wcd |
| Esperion Therapeutics, INC. | $38.40 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.74 | 2023 | Lifevest |
| Boston Scientific Corporation | $17.74 | 2023 | Watchman Access System |
| Amgen INC. | $16.93 | 2023 | Repatha |
| Amarin Pharma, INC. | $14.90 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Laporte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.